We were delighted to speak with Jean-Frederic Colombel (Icahn School of Medicine at Mount Sinai, New York, US) around his talk on ‘Overcoming the Plateau in IBD Treatment’ which was presented at the virtual 2021 Crohn’s & Colitis Congress, 21-24 January, 2021.
- Could you tell us about the plateau in drug efficacy that occurs with current treatment options? (0:25)
- How important is the personalised paradigm in the treatment of IBD? (2:28)
- What are the unmet needs for biomarkers in the personalisation of IBD treatment and what has been achieved so far? (3:30)
- What is ‘Rational polypharmacy’ and what is the potential of combining therapies for overcoming the plateau in IBD treatment? (5:27)
- Is prevention during the pre-clinical phase of IBD the path to ‘breaking the ceiling’ in treatment? (9:50)
Disclosures: Jean-Frederic Colombel has received research grants from AbbVie, Janssen Pharmaceuticals and Takeda; has received payment for lectures from AbbVie, Amgen, Allergan, Bristol-Myers Squibb Company, Ferring Pharmaceuticals, Shire, Takeda and Tillots; has received consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Gilead, Iterative Scopes, Ipsen, Immunic, lmtbio, Inotrem, Janssen Pharmaceuticals, Landos, LimmaTech Biologics AG, Medimmune, Merck, Novartis, O Mass, Otsuka, Pfizer, Shire, Takeda, Tigenix, Viela bio; and hold stock options in Intestinal Biotech Development.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of CCC 2021 (Virtual).
Share this Video
Related Videos In Inflammatory Bowel Disease
Marc Ferratnte, UEG 2021: Filgotinib SELECTION Study Results in Ulcerative Colitis
touchIMMUNOLOGY were delighted to speak with Dr Marc Ferrante (University Hospital Leuven, Leuven, Belgium) about the results from the phase 2B/3 study of filgotinib in patients with ulcerative colitis as well as the use of the Partial Mayo Clinical Score in measuring outcomes. His presentation entitled ‘EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ […]
Marc Ferrante, UEG 2021: Risankizumab as a Maintenance Therapy for Crohn’s Disease
Dr Marc Ferrante (University Hospital Leuven, Leuven, Belgium) kindly took the time to speak with touchIMMUNOLOGY about the 52-week results from the phase 3 FORTIFY study investigating the efficacy and safety of risankizumab as a maintenance treatment in patients with Crohn’s disease. His presentation entitled ‘EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS […]
Marc Ferrante, UEG 2021: Unmet Needs in Managing Crohn’s Disease
It was a pleasure to discuss with Dr Marc Ferrante (University Hospital Leuven, Leuven, Belgium) the current unmet needs in the treatment of patients with Crohn’s disease. Disclosures: Dr Marc Ferrante has received grants from Amgen, Biogen, Janssen, Pfizer and Takeda; personal fees from, Abbvie, Amgen, Biogen, Boehringer Ingelheim, Celltrion, Falk, Ferring, Janssen, Lamepro, Eli […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!